Skip to main content
OpenTrials
Completed

NCT Number: NCT02411318

Influence of Lifestyle Factors on Neutrophil Migration Pilot Study

This study will determine how common lifestyle practices affect the behavior of neutrophils (a type of immune cell) at shorter time scales than previously possible.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Wisconsin

Madison, Wisconsin, 53705, United States

About this study

This study will investigate how external factors implicated in immunity such as exercise, caffeine ingestion, ethanol, glucose, and glucose and caffeine ingestion influence neutrophil migration.

Neutrophils are the most prominent immune cell in human blood and are involved in a complex equilibrium of immune protection and autoimmune damage. Their recruitment to an inflammatory or wounding site is controlled by the sensing and directed migration to a concentration gradient of attractant molecules, a process called chemotaxis. Immune cells are also implicated in many diseases including cancer. The ability to measure the amplitude of a response over time for a specific patient, and the variation of this response when the patient engages in certain activities or consumes certain substances will improve understanding of how certain lifestyle factors impact the immune response. Traditional assays require large volumes of blood and a long purification process, which may affect neutrophil function and strictly limits the number of draws possible from a single patient. The novel microfluidic assay proposed limits these drawbacks as it has the capability to purify neutrophils from a 3 µL drop of blood in less than 5 minutes and measure their chemotaxis in a gradient of chemokines. Critically, the proposed studies will begin to fill a gap in current understanding of immune response as previous studies focused on single endpoints likely missing early events in the response to external stimulus. Understanding this temporal response may have implications in the development of new treatments as well as improvements in diagnosis of improper immune response.

The KOALA (Kit On A Lid Assay) approach was developed in Professor Dave Beebe's lab and has been validated in a mouse model and in human asthmatic patients. In a collaboration with Dr. Anna Huttenlocher, it has been shown that, in contrast to traditional neutrophil purification, KOALA can be performed with small volumes of blood, and a much quicker purification time.

Due to its unique qualities, KOALA allows for repeated evaluation of neutrophil adhesion and chemotaxis properties, thus making it an attractive method for studying dynamic neutrophil changes that may occur as a result of an external factor.

Using traditional macrobiology tools, researchers have identified several factors that may play important roles in reducing neutrophil responsiveness and migration ability. Lifestyle and diet factors, amongst others, have been shown to impact neutrophil count, migration and biochemical function. For example, sleep deprivation has been linked with higher neutrophil count, despite a known immuno-depressive effect. Physical exercise results in increased neutrophil counts and increased neutrophil degranulation. Dietary factors, such as caffeine and ethanol have been shown to impact immune function.

Blood glucose will be tested at each time point using a blood glucose monitor to determine whether the lifestyle factor is affecting blood glucose (and consequently, neutrophil function). Alcohol consumption can cause both high and low blood sugar. Specifically, while low doses of alcohol may have a protective effect against risk of diabetes and metabolic syndrome, heavy drinking has been associated with higher glucose levels, resulting in increased risk of both diabetes and metabolic syndrome. Similarly, acute ingestion of caffeine has been shown to increase blood glucose levels, but several epidemiological studies have shown regular coffee consumption in associated with a lower risk of type 2 diabetes. Measuring blood glucose on subjects in the glucose study may show dose dependent effects on neutrophils.

To build on this research, the investigators intend to probe the role of these lifestyle factors on neutrophil migration over much shorter time scales than has been previously studied. The investigators propose to examine the effects of exercise, ethanol ingestion and caffeine consumption on neutrophil behavior.

Whole blood obtained from subjects by finger stick will be used in KOALA to isolate neutrophils. Neutrophil function will be assessed by measuring absolute migration speed, chemotactic index and chemotaxis velocity (directional velocity toward the formation of the gradient of chemoattractant).

The primary outcome of this study will be to determine whether exercise, caffeine consumption, ethanol, glucose and combined glucose and caffeine ingestion affect neutrophil chemotactic velocity. The secondary outcomes are to determine whether exercise, caffeine consumption, ethanol, glucose and combined glucose and caffeine ingestion affect the absolute speed and chemotactic index of neutrophils. The investigators will also assess whether cytokine profiles in the blood change as a result of engaging int he specified lifestyle factors.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Capacity to provide informed consent and ability to speak and read English.
  • Male or female with no chronic or acute health concerns that might affect subject safety during the study or interfere with the study results
  • No intake of medication that the researchers believe will significantly influence immune function in the 48 hours proceeding the lancet puncture (examples given in the section entitled "Exclusion Criteria")
  • In good physical health
  • Regularly exercise at least 30 minutes 3 times per week (exercise cohort)

Exclusion criteria

  • Currently participating in another clinical trial
  • History of significant systemic disease (eg. cancer, infection, hematological, renal, hepatic, coronary artery disease or other cardiovascular disease, endocrinologic, neurologic, rheumatologic, or gastrointestinal disease)
  • Use of beta blockers or corticosteroids
  • Currently taking medications that are not recommended to be taken in conjunction with alcohol
  • Acute illness or evidence of clinically significant active infection
  • Currently receiving immunotherapy
  • Pregnant women
  • Ingested medication (e.g. systemic corticosteroids) within 48 hours preceding the draw that the researchers believe may have an effect on immune response or the immune system
  • Performed any activity that conflicts (eg. drinking any alcohol prior to the study), in the judgment of the investigator, with the external factor to be tested in the study (if any)
  • Alcoholic or other health conditions for which alcohol consumption is contraindicated
  • Consume more than 7 drinks per week (women alcohol cohort)
  • Consume more than 14 drinks per week (men alcohol cohort)
  • Consume more than three (8 oz.) servings of coffee, caffeinated soft drinks/tea (12 oz.) per day (caffeine cohort)

Treatment and study plan

Exercise

Behavioral

Participants will ride a stationary bike and maintain their target heart rate (according to the American Heart Association guidelines) for 30 minutes.

ProLab 200mg caffeine capsule

Drug

Participants will swallow one ProLab caffeine 200mg tablet.

Ethanol ingestion

Other

Participants will consume a dose of 80 proof alcohol according to their body weight to reach a breath alcohol concentration of 0.05.

Glucose Tolerance Drink

Drug

Participants will consume 100 grams of glucose

Primary outcomes

  1. Change in Exercise-Related Neutrophil Chemotactic Velocity

    Time frame: baseline, 30 min, 60 min

    Participants will ride a stationary bike and maintain their target heart rate for 30 min. Blood samples via lancet will be collected at baseline, 30 min (immediately post intervention), and 60 min.

  2. Change in Caffeine-Related Neutrophil Chemotactic Velocity

    Time frame: baseline, 30 min, 60 min

    Participants will consume a moderate dose of caffeine via 200mg capsule. Blood samples via lancet will be collected at baseline, 30 min (immediately post intervention), and 60 min.

  3. Change in Ethanol-Related Neutrophil Chemotactic Velocity

    Time frame: baseline, 1-3 hours from baseline, up to 2-4 hours from baseline

    Participants will consume a weight-calculated dose of alcohol sufficient to increase their blood alcohol concentration (BAC) to 0.05. Blood samples via lancet will be collected at baseline, 1-3 hours (when BAC reached 0.05) and 1 hour after previous collection.

  4. Change in Glucose-Related Neutrophil Chemotactic Velocity

    Time frame: baseline, 30 min, 60 min

    Participants will consume 100g glucose tolerance drink within 5 minutes. Blood samples via lancet will be collected at baseline, 30 min (immediately post intervention), and 60 min.

  5. Change in Caffeine Plus Glucose-Related Neutrophil Chemotactic Velocity

    Time frame: baseline, 30 min, 60 min

    Participants will consume a moderate dose of caffeine via 200mg capsule and 100g of glucose tolerance drink within 5 min. Blood samples via lancet will be collected at baseline, 30 min (immediately post intervention), and 60 min.

Secondary outcomes

  1. Change in Exercise-Related Neutrophil Absolute Speed

    Time frame: baseline, 30 min, 60 min

    Participants will ride a stationary bike and maintain their target heart rate for 30 min. Blood samples via lancet will be collected at baseline, 30 min (immediately post intervention), and 60 min.

  2. Change in Exercise-Related Neutrophil Chemotactic Index

    Time frame: baseline, 30 min, 60 min

    Participants will ride a stationary bike and maintain their target heart rate for 30 min. Blood samples via lancet will be collected at baseline, 30 min (immediately post intervention), and 60 min.

  3. Change in Caffeine-Related Neutrophil Absolute Speed

    Time frame: baseline, 30 min, 60 min

    Participants will consume a moderate dose of caffeine via 200mg capsule. Blood samples via lancet will be collected at baseline, 30 min (immediately post intervention), and 60 min.

  4. Change in Caffeine-Related Neutrophil Chemotactic Index

    Time frame: baseline, 30 min, 60 min

    Participants will consume a moderate dose of caffeine via 200mg capsule. Blood samples via lancet will be collected at baseline, 30 min (immediately post intervention), and 60 min.

  5. Change in Ethanol-Related Neutrophil Absolute Speed

    Time frame: baseline, 1-3 hours from baseline, up to 2-4 hours from baseline

    Participants will consume a weight-calculated dose of alcohol sufficient to increase their blood alcohol concentration (BAC) to 0.05. Blood samples via lancet will be collected at baseline, 1-3 hours (when BAC reached 0.05) and 1 hour after previous collection.

  6. Change in Ethanol-Related Neutrophil Chemotactic Index

    Time frame: baseline, 1-3 hours from baseline, up to 2-4 hours from baseline

    Participants will consume a weight-calculated dose of alcohol sufficient to increase their blood alcohol concentration (BAC) to 0.05. Blood samples via lancet will be collected at baseline, 1-3 hours (when BAC reached 0.05) and 1 hour after previous collection.

  7. Change in Glucose-Related Neutrophil Absolute Speed

    Time frame: baseline, 30 min, 60 min

    Participants will consume 100g glucose tolerance drink within 5 minutes. Blood samples via lancet will be collected at baseline, 30 min (immediately post intervention), and 60 min.

  8. Change in Glucose-Related Neutrophil Chemotactic Index

    Time frame: baseline, 30 min, 60 min

    Participants will consume 100g glucose tolerance drink within 5 minutes. Blood samples via lancet will be collected at baseline, 30 min (immediately post intervention), and 60 min.

  9. Change in Caffeine Plus Glucose-Related Neutrophil Absolute Speed

    Time frame: baseline, 30 min, 60 min

    Participants will consume a moderate dose of caffeine via 200mg capsule and 100g of glucose tolerance drink within 5 min. Blood samples via lancet will be collected at baseline, 30 min (immediately post intervention), and 60 min.

  10. Change in Caffeine Plus Glucose-Related Neutrophil Chemotactic Index

    Time frame: baseline, 30 min, 60 min

    Participants will consume a moderate dose of caffeine via 200mg capsule and 100g of glucose tolerance drink within 5 min. Blood samples via lancet will be collected at baseline, 30 min (immediately post intervention), and 60 min.

Sponsors and collaborators

Lead sponsor

University of Wisconsin, Madison

Other

Registry information

Important dates

Study start
2014
Primary completion
2019
Study completion
2019
First posted
Apr 8, 2015
Registry last updated
Dec 17, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.